Drug General Information (ID: DDIPRY2KIC)
Drug Name			Paricalcitol		Drug Info		Burosumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Parasympathomimetics				Metabolic Agents

Mechanism of Paricalcitol-Burosumab Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Paricalcitol				Burosumab
Mechanism		Hyperphosphatemia				Hyperphosphatemia
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Paricalcitol and Burosumab

Recommended Action
Management		Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment. Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment.

References
1	Product Information. Crysvita (burosumab). Ultragenyx Pharmaceutical, Novato, CA.